Exelixis Reports the US FDA’s Approval of Cabometyx (Cabozantinib) to Treat Advanced Neuroendocrine Tumors (NETs)

Shots:

• The US FDA has approved Cabometyx for treatment-experienced, inoperable, LA/M, well-differentiated pancreatic NET (pNET) & extra-pancreatic NET (epNET) pts (≥12yrs.)
• Approval was based on P-III (CABINET) study assessing Cabometyx (60mg) vs PBO among 298 US pts (2 arms: pNET: n=99; epNET: n=199) that showed improved PFS; data was presented at ESMO 2024 & published in The NEJM
• Additionally, in Jan 2025, NCCN incl. Cabometyx as category 1 preferred regimen for treatment-experienced well-differentiated advanced NETs & as a category 2A for other forms of advanced NETs, with the company planning to initiate STELLAR-311 trial for zanzalintinib vs everolimus in NETs pts by H1’25

Ref: Businesswire | Image: Exelixis 

Related News:- Exelixis Presents 5-year Follow-Up Data from P-III (CheckMate -9ER) of Cabometyx + Opdivo in Renal Cell Carcinoma Patients at ASCO GU 2025

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com